Avanos Medical Acquired for $1.272 Billion, Shares Surge 68%

Written by Emily J. Thompson, Senior Investment Analyst

Source: NASDAQ.COM

Updated: 4 days ago

0mins

AVNS-0.16%

Should l Buy AVNS?

Source: NASDAQ.COM

Acquisition Overview: Avanos Medical has agreed to be acquired by American Industrial Partners in an all-cash deal valued at approximately $1.272 billion, with shareholders receiving $25.00 per share, representing a 72.1% premium over the closing price on April 13, 2026, indicating strong market confidence.
Board Approval: The acquisition was unanimously approved by Avanos' Board of Directors, with Chair Gary Blackford stating that the agreement reflects strong business momentum and represents the best path to maximize shareholder value, showcasing management's confidence in the future.
Strategic Partnership Outlook: CEO David Pacitti emphasized that partnering with AIP will advance Avanos' innovation roadmap and strengthen its competitive position, indicating that the acquisition will provide the company with enhanced resources and flexibility to support future growth.
Post-Transaction Implications: Upon completion, Avanos will become a private company, and its common stock will be delisted from the New York Stock Exchange, with the deal expected to close in the second half of 2026, reflecting a new positioning for the company in the market.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy AVNS?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on AVNS

About AVNS

Avanos Medical, Inc. is a medical technology company focused on delivering medical device solutions. It offers healthcare needs, such as providing nutrition to patients from hospital to home and reducing the use of opioids while helping patients move from surgery to recovery. Specialty Nutrition Systems portfolio of products includes enteral feeding, which consist of MIC-KEY enteral feeding tubes and Corpak patient feeding solutions, and Neonate solutions feeding products consist of NeoMed neonatal and pediatric feeding solutions. It also includes TKO, an anti-reflux needleless connector technology, which is used in Neonatal and Pediatric Intensive Care Units. The Pain Management and Recovery portfolio of products includes surgical pain and recovery products such as ON-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems and Radiofrequency Ablation solutions, which provide invasive pain relief therapies, such as COOLIEF, Trident and ESSENTEC RFA products.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Investor Rights Law Firm Investigates Multiple Companies

3 days agoGlobenewswire

Investigation Focus: Halper Sadeh LLC is investigating Avanos Medical, Inc. (NYSE: AVNS) for potential violations of federal securities laws related to its sale to American Industrial Partners for $25.00 per share in cash, raising concerns about fiduciary duties to shareholders.
Shareholder Rights: Leggett & Platt, Incorporated (NYSE: LEG) is set to sell to Somnigroup International Inc. for 0.1455 shares of Somnigroup common stock per Leggett share, resulting in Leggett shareholders owning approximately 9% of the combined entity, with Halper Sadeh LLC encouraging shareholders to explore their rights and options.
Cash Transaction: Soleno Therapeutics, Inc. (NASDAQ: SLNO) plans to sell to Neurocrine Biosciences for $53.00 per share in cash, prompting Halper Sadeh LLC to remind shareholders of their potential legal rights.
Management Involvement: Forian Inc. (NASDAQ: FORA) is being sold for $2.17 per share in cash to a consortium led by CEO Max Wygod, with Halper Sadeh LLC potentially seeking increased consideration and other remedies to protect shareholder interests.

Investigations into Multiple Medical Company Mergers

3 days agoGlobenewswire

Avanos Medical Acquisition: Avanos Medical is set to be acquired by American Industrial Partners for $25.00 per share in an all-cash deal valued at approximately $1.272 billion, with investigations focusing on whether the board breached fiduciary duties by failing to ensure a fair process for shareholders.
Leggett & Platt Merger: Leggett & Platt will be acquired by Somnigroup International in an all-stock transaction valued at around $2.5 billion, where shareholders will receive 0.1455 shares of Somnigroup for each share of Leggett & Platt, raising concerns about potential fiduciary breaches by the board.
Soleno Therapeutics Acquisition: Soleno is to be acquired by Neurocrine Biosciences for $53.00 per share in cash, representing a total equity value of approximately $2.9 billion, with investigations questioning the fairness of the deal given it is below the company's 52-week high of $90.32.
Forian, Inc. Investigation: Forian will be acquired by an entity affiliated with CEO Max Wygod for $2.17 per share in cash, with investigations looking into whether the board failed to conduct a fair process, potentially impacting shareholder value.

Avanos Acquired for $1.27 Billion in Cash Deal

4 days agostocktwits

Acquisition Agreement Details: Avanos has entered into an agreement with American Industrial Partners for an acquisition valued at approximately $1.27 billion, with shareholders receiving $25 per share in cash, representing a 72% premium over the last closing price, indicating strong market confidence in the deal.
Stock Price Reaction: Following the announcement, Avanos' stock surged 70%, marking its largest single-day gain ever, reaching its highest level since September 2024, reflecting investor optimism about the company's future prospects.
Financial Overview: As of Q4 2025, Avanos reported a cash balance of $89.8 million, down from $107.7 million at the end of 2024, with total debt at $100.5 million, highlighting financial pressures prior to the acquisition.
Future Outlook: Avanos expects net sales for 2026 to range between $700 million and $720 million, with projected earnings of $0.90 to $1.10 per share, indicating that the company aims to maintain stable revenue growth post-acquisition despite a net loss of $72.9 million in the previous year.

Investor Rights Law Firm Investigates Multiple Companies

4 days agoPRnewswire

Shareholder Rights Investigation: Halper Sadeh LLC is investigating Avanos Medical, Inc.'s sale to American Industrial Partners for $25.00 per share in cash, which may infringe on shareholder rights.
Transaction Structure Analysis: Leggett & Platt, Incorporated is selling to Somnigroup International Inc. for 0.1455 shares of common stock per share, resulting in Leggett & Platt shareholders owning approximately 9% of the combined company, potentially affecting their future equity.
Cash Transaction Impact: Assertio Holdings, Inc. is being sold to Garda Therapeutics for $18.00 per share in cash and a contingent value right, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures to protect shareholder interests.
Legal Service Commitment: Halper Sadeh LLC offers legal services on a contingency fee basis, aiming to provide relief for investors affected by securities fraud and corporate misconduct, emphasizing their expertise in safeguarding investor rights.

Ademi LLP Investigates Avanos for Possible Fiduciary Breaches

4 days agoPRnewswire

Investigation Launched: Ademi LLP is investigating Avanos regarding its transaction with American Industrial, focusing on potential breaches of fiduciary duty and legal violations that may affect shareholder rights.
Transaction Details: Avanos shareholders are set to receive $25.00 per share in an all-cash deal valued at approximately $1.272 billion, indicating a substantial return but raising concerns about the board's conduct.
Competition Restrictions: The transaction agreement imposes significant penalties on Avanos for accepting competing bids, potentially undermining the best interests of shareholders by limiting their options.
Board Accountability: The investigation will scrutinize whether the Avanos board has fulfilled its fiduciary duties to all shareholders, ensuring that their decisions align with the maximum interests of the shareholders.